Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Capital Expenditures (2016 - 2025)

CytomX Therapeutics' Capital Expenditures history spans 12 years, with the latest figure at -$19000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 91.44% year-over-year to -$19000.0; the TTM value through Sep 2025 reached -$203000.0, up 24.54%, while the annual FY2024 figure was $8000.0, 89.33% down from the prior year.
  • Capital Expenditures reached -$19000.0 in Q4 2025 per CTMX's latest filing, up from -$127000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q3 2021 to a low of -$928000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $180631.6, with a median of $146000.0 recorded in 2025.
  • The largest YoY upside for Capital Expenditures was 501.64% in 2021 against a maximum downside of 2608.11% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $245000.0 in 2021, then fell by 25.71% to $182000.0 in 2022, then plummeted by 374.18% to -$499000.0 in 2023, then soared by 55.51% to -$222000.0 in 2024, then surged by 91.44% to -$19000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Capital Expenditures are -$19000.0 (Q4 2025), -$127000.0 (Q3 2025), and $146000.0 (Q2 2025).